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Introduction: Impaired immune function during the perioperative period may be associated 
with worse short- and long-term outcomes. Morphine is considered a major contributor to 
immune modulation. 
Patients and methods: We performed a pilot study to investigate postoperative immune 
function by analyzing peripheral blood mononuclear cells’ functionality and cytokine produc-
tion in 16 patients undergoing major abdominal surgery. All patients were treated with intra-
venous (i.v.) patient-controlled analgesia with morphine and continuous wound infusion with 
ropivacaine+methylprednisolone for 24 hours. After 24 hours, patients were randomized into 
two groups, one continuing intrawound infusion and the other receiving only i.v. analgesia. We 
evaluated lymphoproliferation and cytokine production by peripheral blood mononuclear cells 
at the end of surgery and at 24 and 48 hours postoperatively. 
Results: A significant reduction in TNF-α, IL-2, IFN-γ and lymphoproliferation was observed 
immediately after surgery, indicating impaired cell-mediated immunity. TNF-α and IFN-γ 
remained suppressed up to 48 hours after surgery, while a trend to normalization was observed 
for IL-2 and lymphoproliferation, irrespective of the treatment group. A significant inverse 
correlation was present between age and morphine and between age and lymphoproliferation. 
No negative correlation was present between morphine and cytokine production. We did not 
find any differences within the two groups between 24 and 48 hours in terms of morphine 
consumption and immune responses. 
Conclusion: A relevant depression of cell-mediated immunity is associated with major surgery 
and persists despite optimal analgesia. Even though morphine may participate in immunosup-
pression, we did not retrieve any dose-related effect.
Keywords: opioids, postoperative pain, cytokines, immunomodulation, lymphoproliferation, 
surgery
Introduction
The perioperative period of any major surgery is accompanied by immune suppres-
sion that results from the interaction of several factors, including drugs used for 
postoperative pain control.1–4 An impaired immune system in the perioperative period 
has important clinical implications because it is associated with an increased risk of 
developing postoperative infections and sepsis.4,5 Furthermore, the cell-mediated 
immunity is important in cancer surgery for reducing metastatic spread.3,6–9 On one 
hand, surgical stress can activate the sympathetic nervous system (SNS) and the hypo-
thalamic–pituitary–adrenal (HPA) axis to induce the neuroendocrine response,1,4 which 
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inhibits T-cell responses; following major surgery, cellular 
immunity remains suppressed for several days and cytokine 
production is profoundly affected.4,10 On the other hand, pain 
itself is immune depressant; appropriate postoperative pain 
control is therefore mandatory, and opioids are often used 
as intra- and postoperative analgesics.
However, opioids (morphine in particular) have consis-
tently been considered as important factors responsible for 
immune modulation in the perioperative period.8,11–16
Experimental and clinical data indicate that morphine 
exerts immunosuppressive activity, decreasing innate and 
both cell-mediated and humoral adaptive immunity, acting 
on lymphocytes and macrophages. Opioids have been shown 
to affect nearly all aspects of the immune system including 
macrophages, neutrophils, T cells and NK cells.11 Cellular 
immunity, the system primarily responsible for host antitumor 
defense, is suppressed with both acute and chronic opioid 
exposure. Opioids modulate immune function by either 
interacting directly in the periphery with mu-opioid recep-
tors (MOR) expressed by lymphocytes and mononuclear 
phagocytes or activating central MOR that can stimulate 
HPA axis.17–20
Since opioid-induced immune effects are dose related,21,22 
reduced morphine intake toward opioid-sparing perioperative 
care could be beneficial, especially in oncologic surgery.21–26
For these reasons, in this pilot study (included in a larger 
clinical trial on multimodal analgesia), functional measure-
ment of immune responses (lymphoproliferation, T-helper 
1/2 – Th1/Th2 and macrophage cytokine production) was 
performed in patients undergoing major surgery to investigate 
the effects of surgical stress and opioids on perioperative 
immune function.
Patients and methods
Patients
This pilot study was performed on a smaller sample of 
patients enrolled in a Phase III, double-blind, randomized 
clinical trial investigating the efficacy and safety of prolonged 
continuous wound infusion (CWI) after major abdominal 
surgery. A total of 16 patients, American Society of Anes-
thesiologists’ I–II–III, scheduled to use patient-controlled 
analgesia (PCA) with morphine for postoperative pain control 
after major abdominal surgery for cancer (biliopancreatic, 
hepatic, bowel cancers) were enrolled. Regular use of opioid 
analgesics and immunosuppressant drugs, history of drugs 
and/or alcohol abuse, postoperative hospitalization in inten-
sive care with sedation and/or mechanical ventilation, neuro-
logical disorders, any heart conduction disease, any cognitive 
or mental disorder hindering to sign an informed consent, 
body mass index >30, diabetes (type I or II), allergy to study 
drugs and use of epidural analgesia were exclusion criteria.
On the day of surgery, patients were provided with 
standard monitoring (electrocardiography [ECG], oxygen 
saturation, noninvasive blood pressure) plus invasive pres-
sure monitoring.
The study was approved by the ethical committee of each 
participating center (Fondazione IRCCS Policlinico San 
Matteo, Pavia; University Hospital, Parma and Humanitas 
Research Center, Milan), and all patients signed a written 
informed consent. The trial was registered on Clinicaltri-
als.gov (NCT02002663 – Principal Investigator Massimo 
Allegri, MD).27
Three centers were involved, but all the analyses that are 
part of the current study were carried on consecutive patients 
enrolled between April 2015 and July 2016 at Humanitas 
Research Center, Milan.
Since functional measures need fresh blood to be reliable, 
this choice was made to quickly deliver fresh blood samples 
from the closest hospital to the research laboratory (Milan 
University).
The primary end point of this pilot study was to evaluate 
immune responses and their correlation with opioid con-
sumption in the first 24 hours. The secondary end point was 
to evaluate immune response in the second day of treatment 
according to the allocation group, and its correlation with 
opioid consumption.
We also investigated correlation between immune 
responses and age or sex.
Treatments
Details about the main randomized controlled trial (RCT), 
including inclusion and exclusion criteria, treatments, clinical 
evaluations and randomization/allocation/blinding are included 
in our previously published article.27 We summarize here only 
those information that are relevant to the current study.
Patients received general anesthesia and intraoperative 
analgesia with opioids (either fentanyl 0.2 µg/kg and/or 
remifentanil 0.1–0.25 mg/kg/min). All patients received 
morphine (0.15 mg/kg) 30–45 minutes before the end of 
surgery and were then all treated with an intravenous PCA 
with morphine and ketorolac (8 mg) for the next 48 hours, 
regardless of the allocation group. An infusion catheter 
(Plan1-Health PAINfusor®; Plan1Health s.r.l. Udine, Italy) 
was placed by the surgeon in the fascial plane between 
peritoneum and transversalis fascia, and 10 mL of 0.2% 
ropivacaine was administered immediately after muscular 
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plane closure; the catheter was then connected to an elec-
tronic pump (CADD®-Solis; Smith’s Medical Italia, Latina 
Scalo, Italy). All patients were infused with the same active 
treatment (ropivacaine 0.2%+methylprednisolone 1 mg/kg, 
10 mL/h) for 24 hours and were then randomized to receive 
either active treatment (Group A: ropivacaine 0.2%+methyl-
prednisolone 1 mg/kg, 10 mL/h) or placebo (Group B: saline 
10 mL/h). On a daily basis, all patients were evaluated after 
surgery by the acute pain service (APS) and twice a day by 
the surgeons as part of their current clinical practice. Pain 
values, analgesic consumption, any drug-related side effect 
and catheter-related complication (such as occlusion and 
dislodgment) were recorded. Pain at rest and pain at move-
ment (i.e., coughing and deep inspiration) were evaluated by 
Numeric Rating Scale (NRS; 11-point scale, from 0=no pain 
to 10=worst imaginable pain).
Blood sample collection
Blood samples were taken before anesthesia induction, at the 
end of surgery and at 24 and 48 hours from the end of surgery 
and collected in EDTA-containing vials. All blood samples 
were analyzed within 24 hours of collection.
Mononuclear cell cultures
Peripheral blood mononuclear cells (PBMC) were isolated 
using Ficoll-Paque Premium (GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden). Cells viability was checked by trypan 
blue exclusion test.
PBMC were diluted in Roswell Park Memorial Insti-
tute (RPMI)-1640+10% fetal calf serum (FCS) at the final 
concentration of 2×106 (1 mL/well) and dispensed into 
24-well culture plates. PBMC were incubated with or with-
out 1 µg/mL lipopolysaccharide, which is considered as a 
preferential activator of the monocyte/macrophage lineage, 
for IL-1β, IL-10 and TNF-α stimulation and with 10 µg/mL 
phytohemagglutinin (PHA) for Th1 (IL-2, IFN-γ) and Th2 
(IL-4, IL-10) cytokine stimulation. The stimuli were added 
to cultures in a final volume of 1 mL/well in RPMI-1640 
plus 10% FCS, 1% glutamine, 2% streptomycin solution and 
0.1% 2-mercaptoethanol (complete RPMI). After 24 hours 
of culture at 37°C in 5% CO
2
 and 95% air, the supernatants 
were collected and stored at -80°C for cytokine evaluation.28
Enzyme-linked immunosorbent assay 
(ELISA)
Cytokine concentration was determined using ultra-sensitive 
ELISA kits according to the manufacturer’s instructions. 
ELISA Ready-Set-Go! systems for human IL-1β, IL-10, 
TNF-α, IL-2, IFN-γ and IL-4 were purchased from eBio-
science (San Diego, CA, USA). Cytokines produced are 
reported as concentrations in culture media of stimulating 
cells (pg/mL).
Lymphocyte proliferation
Lymphoproliferation was assessed before surgery, at the end 
of surgery and 48 hours postoperatively.
In vitro lymphocyte proliferation was analyzed using 
5-bromo-2′-deoxyuridine (BrdU) labeling of DNA-synthe-
sizing cells using FITC BrdU Flow Kit (BD PharmingenTM, 
San Diego, CA, USA). In all, 106 lymphocytes were seeded 
in complete RPMI with or without 10 µg/mL PHA at the 
final volume of 1 mL in 5 mL sterile tubes. All samples were 
tested in duplicate. After 48 hours of culture at 37°C in 5% 
CO
2
 and 95% air in the presence or absence of PHA, BrdU 
labeling reagent (final concentration: 10 µM) was added and 
cells were cultured for further 24 hours. Cells were processed 
according to manufacturer’s instructions and then fixed for 
30 minutes and incubated with anti-BrdU for 30 minutes at 
room temperature. Cells were resuspended in 1 mL of stain-
ing buffer (Dulbecco’s PBS+3% FCS+0.09% sodium azide) 
and analyzed by cytofluorimetric analysis. Culture medium, 
cells cultured without PHA and cells incubated with anti-
BrdU in the absence of BrdU were used as controls.
A cytofluorimetric analysis of fluorescent cells (FITC-
BrdU positive cells) evaluated the percentage of cells that 
have incorporated BrdU. All flow cytometry analysis was 
performed by FACS Calibur flow cytometer (488Ex/620Em; 
Becton Dickinson, San Jose, CA, USA) acquiring a maxi-
mum of 20×105 cells/sample.
Statistical analysis
Results are presented as mean±standard error of mean (SEM). 
Normality of data distribution was assessed by the Jarque–
Bera test. Statistical analyses were performed using one-way 
analysis of variance (ANOVA) for parametric results, when 
indicated follow-up analysis was performed using Bonferroni 
post tests for multiple comparisons. Paired Student’s t-test 
was used for the comparison between two groups; to assess 
possible correlations, Pearson correlation test was used. All 
the statistical analysis were performed using GraphPad Prism 
5 Software (GraphPad Software, Inc., La Jolla, CA, USA). 
Differences were considered as significant at p<0.05.
Since treatment was the same in both groups in the first 
24 hours, we considered all patients as one group and dif-
ferentiated between two groups only for the second postop-
erative day (24–48 hours from surgery).
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Results
A total of 16 patients were included in the study (mean 
age 64±11 years, mean±SD; eight males/eight females): 
nine patients were randomized to Group A (mean age 
63.8±11.7 years; six males/three females) and seven patients 
to Group B (mean age 63.4±12.74 years; two males/five 
females). Duration of surgery for each patient is reported in 
Table 1. Only one of the 16 patients needed blood transfusions 
preoperatively (Group A), while three patients received intra-
operative transfusion (two in Group A and one in Group B). 
Since immune parameters of transfused patients were never 
different from those of non-transfused one (data not shown), 
we did not exclude them from the analysis. Patients reported 
good pain relief all along the postoperative period, as shown 
by NRS values at rest and movement (Figure 1). No signifi-
cant differences between groups were observed.
Cytokines
Figure 2 reports the production of cytokines after in vitro 
stimulation with lipopolysaccharide.
As reported in Figure 2A, surgery does not influence the 
production of the proinflammatory cytokine IL-1β, which 
remains unmodified along the 48 hours of observation, 
without any significant difference between the two groups. In 
contrast, the other relevant proinflammatory cytokine TNF-α 
(Figure 2B) is significantly decreased after the surgery, and 
Table 1 Duration of surgery and individual morphine consumption of patients at the different times of the study
Patients Surgery duration 
(minutes)
Morphine 
0–24 hours (mg)
Morphine 
24–48 hours (mg)
Morphine 
0–48 hours (mg)
Group
1 429 8 2 10 A
2 609 4 10 14
3 253 18 10 28
6 460 34 31 65
8 612 20 10 30
12 308 18 0 18
14 267 3 1 4
15 366 6 6 12
16 457 65 35 100
4 365 12 8 20 B
5 372 35 12 47
7 288 8 4 12
9 234 49 27 76
10 476 39 12 51
11 404 16 10 26
13 247 3 2 5
Morphine intake 
(mg), mean±SEM
21.13±4.58 11.25±2.66* 32.38±6.70 A+B
Notes: *p<0.05 v.s. 0–24 hours (paired t-test). Active treatment (Group A: ropivacaine 0.2%+methylprednisolone 1 mg/kg, 10 mL/h); placebo (Group B: saline 10 mL/h).
Abbreviation: SEM, standard error of mean.
4
n=16 n=9 n=9 n=7n=7 n=16
3
2
1
0
At rest At movement
Post-surgery
24 hours after surgery
48 hours after surgery – Group A
48 hours after surgery – Group B
S
co
re
 N
R
S
Figure 1 At rest and movement NRS values recorded immediately after the end of surgery and 24 and 48 hours later.
Notes: Data from post- and 24 hours after surgery include all patients (n=16), while data at 48 hours represent patients divided into Group A (n=9) or Group B (n=7). Values 
are mean±SEM. Active treatment (Group A: ropivacaine 0.2%+methylprednisolone 1 mg/kg, 10 mL/h); placebo (Group B: saline 10 mL/h).
Abbreviations: NRS, Numeric Rating Scale; SEM, standard error of mean.
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the levels remained lower than preoperatively also at 24 and 
48 hours in both Group A and Group B. Figure 2C shows the 
production of the anti-inflammatory cytokine IL-10, which 
is not altered at any time.
Data on Th1 and Th2 cytokine production are reported 
in Figure 3. Both IFN-γ (Figure 3A) and IL-2 (Figure 3B), 
typical Th1 cytokines, are significantly reduced at the end 
of surgery. IFN-γ remains reduced after 24 and 48 hours, 
irrespective of the allocation group, while a trend toward 
normalization was observed for IL-2 at 24 and 48 hours in 
both groups.
On the other hand, the Th2 cytokines IL-4 and IL-10 do 
not appear to be altered either by surgery or postoperative 
pain treatments (Figure 3C and D).
Lymphoproliferation
As reported in Figure 4, a significant reduction in lympho-
proliferation was observed immediately after surgery in all 
100
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48 hours – B
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-1
0 
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/m
L
C
Figure 2 Cytokine levels released by PBMC after LPS stimulation.
Notes: Blood samples were obtained before surgery, immediately after the end of surgery and 24 and 48 hours later. PBMC were stimulated in vitro for 24 hours with 
1 µg/mL LPS, and IL-β (A), TNF-α (B) and IL-10 (C) released in media were evaluated by ELISA. Data from pre-, post- and 24 hours after surgery include all patients (n=16), 
while data at 48 hours represent patients divided into Group A (n=9) or Group B (n=7) (refer the “Patients and methods” section). Values are mean±SEM. *p<0.05, **p<0.01 
and ***p<0.001 v.s. presurgery cytokine levels. Active treatment (Group A: ropivacaine 0.2%+methylprednisolone 1 mg/kg, 10 mL/h); placebo (Group B: saline 10 mL/h).
Abbreviations: PBMC, peripheral blood mononuclear cells; LPS, lipopolysaccharide; ELISA, enzyme-linked immunosorbent assay; SEM, standard error of mean.
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Figure 3 Cytokine levels released by PBMC after PHA stimulation.
Notes: Blood samples were obtained before surgery, immediately after the end of surgery and 24 and 48 hours later. PBMC were stimulated in vitro for 24 hours with 10 µg/
mL PHA, and INF-γ (A), IL-2 (B), IL-4 (C) and IL-10 (D) released in media were evaluated by ELISA. Data from pre-, post- and 24 hours after surgery include all patients 
(n=16), while data at 48 hours represent patients divided into Group A (n=9) or Group B (n=7; refer the “Patients and methods” section). Values are mean±SEM. *p<0.05 
and **p<0.01 v.s. presurgery cytokine levels. Active treatment (Group A: ropivacaine 0.2%+methylprednisolone 1 mg/kg, 10 mL/h); placebo (Group B: saline 10 mL/h).
Abbreviations: PBMC, peripheral blood mononuclear cells; PHA, phytohemagglutinin; ELISA, enzyme-linked immunosorbent assay; SEM, standard error of mean.
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patients; a trend toward a return to presurgical lymphop-
roliferation was retrieved at 48 hours, without statistically 
significant difference.
Morphine consumption, immune 
responses and age
The amount of morphine consumption was different among 
patients, as reported in Table 1. Morphine intake was sig-
nificantly higher in the first 24 hours than in the second 
postoperative day (21.13±4.58 mg vs. 11.25±2.66 mg, 
mean±SEM; p<0.05 according to paired t-test). In our 
cohort, we did not find any statistical significant difference 
in opioid consumption (Group A: 11.7±4.3 mg; Group B: 
10.7±3.1 mg, mean±SEM; p=0.83 according to t-test) in 
the second day after surgery (24–48 hours) between the 
two groups.
We therefore correlated morphine consumption and the 
immune response within the whole sample, without looking 
at possible differences between the two groups. No inverse 
correlation was determined for any cytokine and morphine 
intake (data not shown). A significant correlation was found 
between total (0–48 hours) morphine consumption and lym-
phoproliferation at 48 hours (Figure 5A).
We found a significant inverse correlation between 
age and morphine intake at all times of evaluation, i.e., 
0–24 hours, 24–48 hours and 0–48 hours (Figure 5B). A 
significant inverse correlation was also evident between age 
and lymphoproliferation (Figure 5C) only when measured 
48 hours after surgery. Duration of surgery did not signifi-
cantly correlate with either any immune parameter studied 
or morphine intake (data not shown).
Discussion
Immune response is severely damaged during the periopera-
tive period, with systemic inflammatory responses accom-
panied by immune depression.3,11 However, it is still unclear 
whether the perioperative analgesic treatment can affect this 
response or not and how postoperative and persistent pain 
do correlate with it.
In this pilot study, we investigated how the cellular 
immune response is affected within the postoperative period 
and how it correlates with opioid consumption in a multi-
modal analgesic approach.
Since a balance between Th1 and Th2 cells is needed 
for a correct homeostasis of the immune system in normal 
conditions,29,30 we measured representative Th1 and Th2 
cytokines.28,31 Furthermore, also the proinflammatory cyto-
kines TNF-α and IL-1β were evaluated, considering their 
relevance in antimicrobial immunity and in immune surveil-
lance against tumors.32
The results obtained clearly confirm that a relevant sup-
pression of cellular immune responses happens after major 
surgery.
Among the investigated cytokines, TNF-α and the Th1 
cytokines IFN-γ and IL-2 are the most affected, suggesting 
a global reduction in cellular immune response. In contrast, 
anti-inflammatory and Th2 cytokines are not altered in our 
cohort. Since IFN-γ/IL-4 ratio is frequently used as index for 
determining T helper profile, a reduction in Th1 activity can 
be hypothesized after surgery.
One of the more relevant points of this study is the 
observation that the immune response has not fully recov-
ered 48 hours after surgery. Some of the cytokines are still 
Pre
0
10
20
30
n=16 n=9
Pre-surgery
Post-surgery
48 hours after surgery – Group A
48 hours after surgery – Group B
n=7
Br
dU
-in
co
rp
or
at
ed
 P
BM
C
 (%
)
**
Post 48 hours – A 48 hours – B
Figure 4 Lymphocyte proliferation.
Notes: Blood samples were obtained before surgery, immediately after the end of surgery and 48 hours later. Cells were stimulated in vitro for 72 hours with 10 µg/mL PHA. 
Proliferation is expressed as percentage of PBMC that incorporated BrdU in 24 hours. Data from pre- and post-surgery include all patients (n=16), while data at 48 hours 
represent patients divided into Group A (n=9) or Group B (n=7; refer the “Patients and methods” section). **p<0.01 vs. Pre-surgery. Active treatment (Group A: ropivacaine 
0.2%+methylprednisolone 1 mg/kg, 10 mL/h); placebo (Group B: saline 10 mL/h).
Abbreviations: PHA, phytohemagglutinin; PBMC, peripheral blood mononuclear cells; BrdU, 5-bromo-2′-deoxyuridine.
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 significantly reduced, while an improvement in IL-2 produc-
tion and lymphoproliferation starts, although not complete. 
Immune dysfunction is therefore partially maintained at 
48 hours, potentially increasing the risk of postoperative 
infection, sepsis or eventually favoring cancer recurrence.
Several factors are known to contribute to immunodepres-
sion. Both surgical stress (with HPA activation) and drugs 
that are used for anesthesia and analgesia can impact immune 
response. Pain itself has a negative impact on immune 
response.33,34 In the postoperative period, an optimal control 
of pain is auspicable, and it is fully achieved in the patients 
of the study. Extensive preclinical studies from ours and other 
groups have demonstrated that postoperative immune func-
tion is usually more rapidly recovered34–36 when pain control 
is obtained with drugs devoid of intrinsic immunomodula-
tory activity; similar results were also reported in a clinical 
study where the intrinsic immunosuppressive morphine was 
compared with the non-immunosuppressive tramadol in a 
group of patients receiving minor surgery.36
All our patients received fentanyl/remifentanil intraop-
eratively and a morphine bolus immediately before the end 
of surgery, just before blood withdrawal for immune evalu-
ation. Both fentanyl and morphine are generally considered 
to be immunosuppressive, and it can be supposed that they 
participate in the reduction of cytokine production and 
lymphoproliferation that we observed after surgery.11,23,37,38
Some authors suggested that the effects of opioids such as 
fentanyl and morphine on immune responses could be dose 
related.11,21,37 A possible bias of our study is related to the fact 
that we do not have two groups with different intraoperative 
opioids intake, but in order to specifically rule out the effect 
of opioids v.s. surgical stress in giving immune dysregula-
tion, an intraoperative complete opioid-free approach would 
be needed.39 Postoperative morphine, as well, may account 
for further immune dysfunction and its duration. Patients 
enrolled in the current cohort are part of a larger multicenter 
study, which was designed to reduce morphine intake from 
24 hours after surgery in the treatment group. The results on 
morphine consumption of the whole sample will be published 
separately. As no difference in morphine consumption was 
observed between the two groups of patients specifically 
included in the current study, we decided to consider the 
amount of morphine for each patient, independent of the 
allocation group. Morphine did not result to be mainly 
responsible for the observed decrease in cytokine production: 
no negative correlation was found between morphine intake 
and any of the immune parameter, indeed. Again, it is difficult 
to dissect the actual perioperative impact of morphine on 
immune function, but since patients were exposed to different 
amounts of morphine and no differences in immunity were 
observed, morphine-induced immunomodulation observed 
in our cohort is unlikely to be dose related.
In addition, no significant difference was found for any of 
the immune parameters in the two groups at 48 hours from 
surgery, despite the saline group displayed a slightly better 
lymphoproliferation. Therefore, although treatment (local 
anesthetic/methylprednisolone) does not have a strong impact 
on immune functionality, potential benefit in terms of anal-
gesia should be balanced with the possible harms (namely, 
steroid-associated immune suppression).
Another important result derived by our study is the con-
firmation of an inverse correlation between age and morphine 
intake: older patients self-administered less morphine, with 
similar pain control but without an impact on immune func-
tion. Factors that may contribute could be related to either 
pharmacokinetic or pharmacodynamic aspects.40–42 It is well 
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known that morphine pharmacokinetic (especially morphine 
metabolism) plays an important role in the final analgesic 
effect, and morphine pharmacokinetic may be different in 
older subjects.43 Different sensitivities to morphine, as well as 
the psychological attitude of decreased self-administration of 
morphine, may be part of the aging process in some patients. 
Finally, the “age” variable may differently impact on opioid 
consumption according to the genetic profile: in our recent 
study on patients undergoing abdominal surgery, a model 
including age and nine single nucleotide polymorphisms 
(SNPs) of genes associated with pain sensitivity and opi-
oid response explained the highest variability of morphine 
consumption.44
Age also seems to play a role in patients’ ability to recover 
from decreased lymphoproliferation: significant inverse cor-
relation exists between lymphoproliferation at 48 hours and 
patient’s age. Since this correlation is absent immediately 
after surgery, we suggest that patients are equally sensitive 
to surgical stress, but younger patients have higher potential 
of recovery.45,46
Surprisingly, we found a positive correlation between 
morphine and lymphoproliferation at 48 hours after surgery. 
However, since older patients had both lower morphine 
intake and lower recovery of lymphoproliferation, we can-
not definitely rule out whether there is a direct relationship 
between morphine and proliferation or rather the “age” 
variable prevails.
In contrast, no differences were found considering male 
or female subjects.
We are aware that other variables or procedures, such as 
the duration of surgery and blood transfusions, could impact 
on immune responses.3,47 Although the duration of surgery 
was different among patients, in our patients’ groups we could 
not find any correlation between the duration of surgery and 
the studied parameters. Moreover, due to the limited number 
of transfused patients in our study, we could not draw any 
conclusion on this aspect.3,47
We acknowledge that the study has some limitations.
The small number of patients is inherent with the nature 
of the study; we wanted to perform a pilot evaluation to 
detect differences in immune function worth to be analyzed 
in further studies, hopefully comparing patients with opioid-
based v.s. non-opioid analgesia. Second, we stopped our 
evaluations at 48 hours after surgery; future studies should 
follow-up for a longer period of time, to evaluate whether 
and when immune function returns to preoperative values.
The strength of our research is that we investigated func-
tional responses of immune cells and not only a differential 
counting of lymphocytes or serum cytokine measurements 
as in the majority of published works.13
Conclusion
This small study indicates that functional immune activity 
is depressed with surgery and that alterations persist despite 
a good postoperative pain control. We also confirmed that 
morphine consumption is modified by age, meanwhile 
showing that recovery of immune depression is more 
difficult in older patients. It is difficult to extrapolate the 
role of morphine in the postoperative period, but it can be 
suggested that the impact of the opioid on immunity is 
an “all or nothing” effect rather than being dose related. 
Further therapeutic approaches must be envisaged in 
order to more effectively prevent or revert postoperative 
immunosuppression.
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